JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy

Each year, September rolls around, and it tends to be the worst month for stocks.

24/7 Wall Street • 10 hours ago

Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 21, 2026

Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.

Zacks Investment Research • Aug 21, 2026

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.

Business Wire • Aug 20, 2026

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Seaport Therapeutics (NASDAQ:SPTX) opened at $25.44 on August 20, 2026, carrying a market capitalization of roughly $1.4 billion.

24/7 Wall Street • Aug 20, 2026

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 19, 2026

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.

24/7 Wall Street • Aug 19, 2026

The Key to Pharma M&A: Never Shopping Hungry

Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.

WSJ • Aug 19, 2026

AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.

Seeking Alpha • Aug 19, 2026

5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now

Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Fifteen/15 portfolio stocks, including MRK, GD, and AMGN, are flagged as overvalued based on proximity to 52-week highs and historic low yields. 5 undervalued candidates for purchase are revealed, supported by both price and historic yield analysis.

Seeking Alpha • Aug 18, 2026